Hyperion Therapeutics, maker of pharmaceuticals to treat hepatology and gastrointenstinal conditions, has raised $13 million of an anticipated $15 million round of debt, according to VentureWire. Contributors have not been disclosed, but the South San Francisco, Calif. company had previously raked in $40 million in a second round of funding from Sofinnova Ventures, Highland Capital Partners, New Enterprise Associates and Washington Research Foundation Capital.
Hyperion is one of the companies that has reported fundraising activity due to new Form D requirements that companies notify the government within 15 days after the sale of securities in an offering.